Summary Photofrin II (dihaematoporphyrin ether/ester, DHE) was labelled with indium-i 11 and its biodistribution in tumour bearing mice compared with that of "'In chloride. The uptake and clearance of "'In labelled DHE differed markedly from that of indium-l 1 chloride in that the former was not taken up by the tissues as much as the latter. Scintillation scanning with a gamma-camera showed marked uptake of both "'In agents at the site of the tumour, but a much lower tissue background (excluding the abdominal organs) for the mice given "'In DHE. Tumour:muscle ratios of dissected tissues were 2-3 times higher in "'In DHE treated animals as compared to the uptake of "'In chloride. There was a distinct difference in the pattern of distribution of the two "'In preparations in the tissues. The major accumulation of "'In chloride was in the kidneys, whereas the highest uptake of "'In DHE was in the liver, the organ in which unlabelled porphyrins accumulate. Extraction and testing of materials from tumours of "'In DHE treated animals indicated that most of the tumour extractable "'In had remained associated with the porphyrin in vivo up to 4 days after injection.
Haematoporphyrin derivative (HPD) is a mixture of substances, some of which are known to localise in tumours and to fluoresce upon exposure to light at the appropriate wavelengths. The consequent release of a singlet oxygen leads to photosensitivity and cytotoxicity, the basis for photodynamic therapy. It is characteristic of many photosensitisers such as porphyrin derivatives, chlorins and phthalocyanins to exhibit preferential accumulation in tumour compared to normal tissue (with the exception of the liver, spleen and kidneys in which these compounds accumulate at high concentrations). Dougherty (1987) and Kessel (1986a,b) have shown that dihaematoporphyrin esters or ethers (DUE) and some oligomers of DHE play major roles in the tumour uptake of HPD. The use of DHE for photodynamic therapy clearly necessitates selective uptake and retention of this agent by the tumour. Hence, a radiolabelled DHE which could be used for in vivo scanning and quantitative measurement of uptake would be of potential value in this form of therapy.
The present work was undertaken to study the in vivo distribution of DHE radiolabelled with indium-111 to determine if this gamma-emitting metalloporphyrin could be used for gamma camera scanning and quantitative measurement of uptake in tumour tissue in vivo. For this purpose DHE (QLT, Phototherapeutics, Inc., Vancouver, BC, Canada) was radiolabelled with indium-111 according to a previously described procedure (Lavallee & Fawwaz, 1986) and its uptake and distribution were measured in tumour bearing mice by scintiscanning and by direct counting of dissected tissues. Photofrin II is a preparation of haematoporphyrin derivative enriched for di-and oligoporphyrin ethers (or esters) and is denoted as DHE in this report. Figure 4a includes results obtained by Saha and Farrer (1975) for the uptake of "'In chloride.
Extraction of DHEfrom tissues
Since the chloroform-methanol extraction technique of Kessel (1986a,b) was unsuitable due to the low solubility of "'In DHE in the solvent used, a technique was adapted from that of Dougherty and Mang (1987) ; this was found to be more satisfactory since indium-i 11 DHE could be clearly separated in the ethylacetate phase (Table I) . However, the final step of the latter procedure using HCI could not be applied to the metallated porphyrin prepared in this study.
The tissues were pressed through a wire mesh into distilled water and frozen overnight. After thawing, the preparation was placed in 5 ml of 150 mm acetic acid and further disrupted by ultrasound. Fifty millilitres of 3:1 ethylacetate:glacial acetic acid was added and the solution stored at 4°C for an hour. This was followed by filtration through glass wool. The mixture was extracted with 25 ml saturated sodium acetate, followed by extraction twice with ethylacetate. About 50-80% of the total tumour radioactivity could be extracted in this way, the remainder staying with the insoluble material and not removed by further ethylacetate extractions. "'In chloride showed a similar degree of tissue retention, but was not extracted with ethylacetate. Recovery rates achieved here are comparable to those obtained by ourselves and other investigators using either 14C labelled porphyrins or unlabelled photosensitisers quantified spectrophotometrically. Figure 1 , pronounced radiolabelling of the tumour area was clearly observed by scintiscanning 1 h and 16 h following the injection of each agent. However, "l'In DHE was found at far lower concentrations in the peripheral tissues (e.g. muscle), as is apparent from the markedly lower uptakes in the contralateral limb and head area, as compared to the higher retention of radioisotope in the tissues of mice given "'In chloride.
The whole body content of "'In for six mice treated with radiolabelled DHE or with the chloride is shown in Figure 2 , which indicates that for DHE, about 2/3 of the injected radioindium was lost from the body after 18 h (after correcting for radioactive decay). In four repeated experiments (6-10 mice per experiment), 1/2 to 2/3 of the injected dose of radiolabelled DHE was lost after the first day, with a much slower release after this period. In contrast, "'In administered as the chloride showed much more pronouced whole body and tissue retention.
By repeated imaging of each animal followed by region-ofinterest (ROI) measurements of the digital images, it was found that the prominent uptakes of "'In chloride or of "'In DHE into the tumour areas were proportional, respectively, to the amount of "'In measured over the contralateral thigh area (Figure 3 ). Although the tumours seemed to take up relatively less of the radiolabelled DHE, compared to "'In given as the chloride, the tumour:muscle ratios found by ROI analyses of imaging data were very similar for both "'In preparations. These in vivo results are in contrast to the tissue dissection analyses, in which tumour:muscle ratios were significantly elevated for "'In DHE (see below).
The question therefore arose whether the radioactivity detected by scintillation scanning over the contralateral thigh represented "'In in the circulating blood or immobilised in the tissues. As shown in Figure 3 , there was little or no fall in the "'In content of peripheral tissue or tumour over 18 h after the first ROI measurement at 2 h, in spite of the known fact that blood concentrations for both DHE and "'In chloride fall markedly during the first day (Bellnier et 1988; Saha & Farrer, 1975 Figure  4a and b. The former appeared at highest concentration in the kidneys (Figure 4a (Gomer & Dougherty, 1979; Bellnier et al., 1988) . Filled squares represent the 24 h tissue distribution of "'.mICI3 as found by Saha and Farrer (1975) .
These results were obtained after injecting the agents i.v. into six tumour-bearing mice.
and Farrer (1975) . In contrast, radiolabelled DHE was taken up mainly by the liver. The organ distribution of DHE was very similar to that reported by Gomer and Dougherty (1979) with 3H and '4C-HPD and by Bellnier et a!. (1988) using '4C-DHE. Data from the latter reports are added to Figure 4b for comparison with the present results using "'In labelled DHE. In another experiment done with animals bearing very large tumours (which were largely necrotic and haemorrhagic), a similar organ distribution was obtained, but much less radiolabelled DHE appeared to enter or be retained by the tumours. Figure 4) , differ from the in vivo ROI analyses in which the ratio of "'In measured by imaging over the tumour area to that over the contralateral thigh was the same for either administered agent (Figure 3) . The difference between the results of in vivo ROI imaging and those obtained by direct counting of dissected tumour and muscle could be due to collection of "'In transferrin in the exudate and edematous tissue surrounding the tumour, since this would be detected by in vivo scintiscanning but not by direct counting of dissected tumour. In Table III , the fraction of injected "'In chloride detected in the tumour area by both methods is compared to the uptake of radiolabelled DHE. It is seen that for "'In DHE, tumour uptake as measured by in vivo scanning compared well with the counting of dissected tumour tissue. In contrast, a large fraction of the injected "'In chloride (about 73%) detected by in vivo imaging over the tumour area was not found in the dissected tumour, and therefore must have localised in adjoining tissues. In support of this hypothesis preliminary analysis of fluid exudate in tumours showed "'In chloride to concentrate after 18 h to three times that present in the blood.
Estimation of dissociation of "'In-DHE in vivo About 80% of the radioactivity extracted from tumours of mice given "'In DHE a day earlier moved in TLC at Rft0.8, whereas the remaining radioactivity did not migrate in the solvent used. In contrast, all the tumour radioactivity extracted a day after given "'In chloride remained at the origin of the TLC strip. This indicated that "'In given as the chloride did not bind or remain bound to any tissue constituent that moved in the silica gel TLC with the solvent solution used.
A further estimate of the degree of dissociation was made, based on the high solubility of "'In DHE in ethylacetate, its low solubility in the aqueous phase, and the opposite solubility of "'In chloride (Table I ). In three separate experiments after "'In DHE injection, 81.8 ± 2.5% (two mice), 74.0 ± 1.5% (three mice) and 87.9±4.6% (five mice) of the tumour-extractable radioindium appeared in the ethyl acetate phase one day after administration. After a 4-day interval, 74.0± 1.5% (three mice) was present in the ethylacetate phase. When "'In was given as the chloride, all tumour or liver "'In passed into the aqueous phase, and the amount extracted into ethylacetate was insignificant.
Extraction from the tissues was never complete. About 1/2 to 3/4 of tumour "'In could be extracted by the technique described from tumours of mice that had received "'In DHE. Less was extractable from the liver. For example, in one experiment with five mice, 33.6 ± 4.3% of tumour "'In was not extractable, and 74.2 ± 2.4% was not extracted from the liver.
or the tumour uptake of the radiolabelled DHE. The results of the experiment are shown graphically in Figure 5 . Four animals received "'In DHE alone, and another four were given both the radiolabelled and 'cold' DHE simultaneously. The animals were killed after 18 h, and the radioindium content of the tumour and tissues was measured by gamma counting of the dissected tissue samples. When the unlabelled DHE was also given, the mean uptake of "'In DHE by the liver was lower by 26% (P<0.01) and the tumour content was found to be 42% higher (P<0.025), than the uptake of radiolabelled DHE given alone.
Discussion
The use of porphyrins in cancer diagnosis and therapy is based both on their phototoxic properties (Raab, 1900; Haussman, 1911) and on the localisation of fluorescent porphyrins in neoplastic tissues (Policard, 1924; Auler & Banzer, 1942; Figge et al., 1948) . A derivative of haematoporphyrin (HPD) has been widely used for tumour detection and photodynamic therapy (PDT) over the past two decades (Lipson et al., 1961; Diamond et al., 1972) . However, it has been difficult to identify the specific tumour localising and phototoxic principles of HPD, which is known to be a complex mixture of different prophyrins. Putative candidates are the dihaematoporphyrin ethers or esters (Dougherty et al., 1984; Kessel & Cheng, 1985) . A purification product of HPD, known commercially as Photofrin II or DHE, contains less than 20% of inactive monomers and more than 80% of the active porphyrin dimers and oligomers. Use of the term DHE in this report refers to the latter product.
Photodynamic therapy with DHE requires its presence in the tumour. Although fluorescence of tumours has been a hallmark of HPD uptake, it does not necessarily follow that the phototoxic compound taken up into the tumour is identical to the fluorescent agent. Therefore, a direct method of assessing the amount of DHE taken up into the tumour in vivo would be of value to determine the probable benefit of PDT, since if the tumour did not taken up the agent, PDT would be ineffective. A radiolabelled DHE that would localise at the tumour site and could be imaged by the gamma-camera would thus be useful for the quantitative estimation of DHE uptake.
A number of workers have investigated the possible use of Effect of unlabelled DHE on the tissue uptake of "'In DHE If "'In DHE were to be used as a 'tracer' for DHE in vivo, it would be important to know the degree to which unlabelled DHE in molecular excess might affect the tissue distribution (3) 5.8±0.4% (6) "'In-DHE 5.3±1.9% (3) 5.2±0.7% (7) Values are means ± s.d. aRegion of interest (ROI) calculations were made 16 h after injection of the radiolabelled agent using six mice and were calculated from the total counts measured over the tumour divided by the total body count obtained from the scintiscan. bThe values for dissected tumour (see also Table II) were expressed as % ofinjected dose per wet weight. Since the total wet mass of the tumour was of the order of 1 g the estimated % total tumour uptake is roughly the same numerically as in this column for comparison with the ROI data. radiolabelled porphyrins and metalloporphyrins for tumour detection in vivo (Figge et al., 1948; Manganiello & Figge, 1951; Bases et al., 1958; Winkelman et al., 1962) , but with varying degrees of success. A major problem with the use of these agents has been their high degree of accumulation in the liver, spleen and kidneys (Hambright et al., 1975; Denechaud et al., 1981; Zanelli & Kaelin, 1981) . Attempts to image tumours with "'In labelled porphyrins have been limited (Vaum et al., 1982; Foster et al., 1985) . In summary of past studies, encouraging tumour localisations of radiolabelled porphyrins have been demonstrated in animal models, but the limited human studies have not shown tumour localisation, possibly due to dissociation of the radiolabel from the porphyrin in vivo or to a metallationinduced loss of the tumour localising property of the porphyrin preparation.
In the present experiments using DBA/2J mice bearing transplanted rhabdomyosarcomas, marked tumour uptake of "'In DHE was observed. The DHE was radiolabelled with "'In by a method adapted from that of Lavallee and Fawwaz (1986) in which heating of DHE was kept not greater than 65°C. The following four experimental findings suggest that "'In DHE has biological properties similar to those of DHE: (a) The tissue and tumour distribution "'In DHE in vivo, as measured from the radioindium content of perfused and dissected tissues, was very similar to that found for '4C and 3H-HPD (Gomer & Dougherty, 1979) and '4C-DHE (Bellnier et al., 1988) as shown in Figure 4 . (b) About 80% of the tumour-extractable "'In that had been administered bound to DHE remained after 1 day or more associated with the porphyrin in vivo, as estimated by its extraction with ethylacetate, whereas "'In given as the chloride was not extracted into the ethylacetate phase. (c) Tissue distribution studies of "'In DHE were carried out using "'In chloride as control to rule out the possibility that "'In may dissociate in vivo from DHE with resultant "'In uptake by the tumour (Saha & Farrer, 1975; Ando et al., 1982) . The tissue distribution of the two agents differed markedly: the former localised primarily in the liver with lower uptake by other tissues; in contrast, the latter rapily accumulated in the kidneys, other tissues showing greater uptake and slower clearance. This is further evidence that the two "'In preparations are handled differently in vivo. (d) The presence of excess unlabelled DHE did not prevent the tumour uptake of "'In DHE. Indeed some enhancement of tumour uptake was observed, with reduced uptake of "'In DHE into the liver ( Figure 5 ). (Figure 2) is presumably due to its binding to transferrin in the plasma, with long lived vascular and extravascular components (Hosain et al., 1969; McIntyre et al., 1974) . In contrast, the rapid turnover of "'In DHE corresponds to the fast blood clearance of 14C-DHE observed by Bellnier et al. (1988) and is likely to be due to rapid passage of the agent into the gut without an hour after administration. In support of this, we have demonstrated (unpublished) marked passage of radioindium into rabbit gut within an hour of "'In DHE i.v. injection.
Metallation of hematoporphyrin in the tetrapyrrole ring is considered to have an inhibitory effect on tumour affinity for the agent (Zanelli & Kaelin, 1981; Wang et al., 1981 (Bugelski et al., 1981) , but another uptake mechanism by tumour may also be involved. Kessel (1986) has described the binding of tumour-localising porphyrins to high and low density lipoproteins (HDL and LDL) which have been shown to transport HPD (Jori et al., 1984; Reyftmann et al., 1984) . Increased LDL receptors have been associated with neoplastic cells (Norata et al., 1984; Gal et al., 1981) 
